Diabetes, Vol 38, Issue 10 1207-1210, Copyright © 1989 by American Diabetes Association

ARTICLES

Deferoxamine therapy in high-ferritin diabetes

P Cutler

Serum ferritin and diabetes control were evaluated in 18 White patients with poorly controlled type II (non-insulin-dependent) diabetes who had no known causes of iron-storage disorder. Serum ferritin levels were found to be elevated with normal serum iron and total iron-binding capacity in 9 of the 18 patients studied. Because excess iron, typified by hemochromatosis, is associated with diabetes, and diabetes has been shown to improve after lowering total-body iron load through repeat venesection, I investigated whether regulating elevated ferritin levels could facilitate diabetes control. Deferoxamine (DFO), a known specific chelator of iron, was used because of its capacity to correct excess iron stores. All 9 patients in the high-ferritin diabetic group and 7 of 9 diabetic control subjects with normal serum ferritin levels were given DFO (10 mg/kg i.v.) twice weekly. Diabetic control, fasting glucose, triglyceride, cholesterol, HbA1c, and serum ferritin levels were monitored. Data show that lowering elevated ferritin levels correlated well with diabetes control and improved fasting glucose, triglyceride, and HbA1c in 8 of 9 patients with high ferritin levels. Lowering normal ferritin levels had no effect on diabetes control or on any of the other parameters in the 7 control subjects. This study shows there is a need to study iron metabolism in poorly controlled diabetes and demonstrates the value of DFO in controlling high-ferritin diabetes.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				K. Saito, N. Ishizaka, M. Hara, G. Matsuzaki, M. Sata, I. Mori, M. Ohno, and R. Nagai Lipid Accumulation and Transforming Growth Factor-{beta} Upregulation in the Kidneys of Rats Administered Angiotensin II Hypertension, November 1, 2005; 46(5): 1180 - 1185. [Abstract] [Full Text] [PDF]

				G. J.S. Cooper, Y.-K. Chan, A. M. Dissanayake, F. E. Leahy, G. F. Keogh, C. M. Frampton, G. D. Gamble, D. H. Brunton, J. R. Baker, and S. D. Poppitt Demonstration of a Hyperglycemia-Driven Pathogenic Abnormality of Copper Homeostasis in Diabetes and Its Reversibility by Selective Chelation: Quantitative Comparisons Between the Biology of Copper and Eight Other Nutritionally Essential Elements in Normal and Diabetic Individuals Diabetes, May 1, 2005; 54(5): 1468 - 1476. [Abstract] [Full Text] [PDF]

				A. Van Campenhout, C. Van Campenhout, A. R. Lagrou, and B. Manuel-y-Keenoy Effects of in Vitro Glycation on Fe3+ Binding and Fe3+ Isoforms of Transferrin Clin. Chem., September 1, 2004; 50(9): 1640 - 1649. [Abstract] [Full Text] [PDF]

				R. Jiang, J. E. Manson, J. B. Meigs, J. Ma, N. Rifai, and F. B. Hu Body Iron Stores in Relation to Risk of Type 2 Diabetes in Apparently Healthy Women JAMA, February 11, 2004; 291(6): 711 - 717. [Abstract] [Full Text] [PDF]

				J. M. Fernandez-Real, G. Penarroja, A. Castro, F. Garcia-Bragado, A. Lopez-Bermejo, and W. Ricart Blood Letting in High-Ferritin Type 2 Diabetes: Effects on vascular reactivity Diabetes Care, December 1, 2002; 25(12): 2249 - 2255. [Abstract] [Full Text] [PDF]

				J. M. Fernandez-Real, A. Lopez-Bermejo, and W. Ricart Cross-Talk Between Iron Metabolism and Diabetes Diabetes, August 1, 2002; 51(8): 2348 - 2354. [Abstract] [Full Text] [PDF]

				J. M. Fernandez-Real, G. Penarroja, A. Castro, F. Garcia-Bragado, I. Hernandez-Aguado, and W. Ricart Blood Letting in High-Ferritin Type 2 Diabetes : Effects on Insulin Sensitivity and {beta}-Cell Function Diabetes, April 1, 2002; 51(4): 1000 - 1004. [Abstract] [Full Text] [PDF]

				M. Fields Nutritional Factors Adversely Influencing the Glucose/Insulin System J. Am. Coll. Nutr., August 1, 1998; 17(4): 317 - 321. [Abstract] [Full Text] [PDF]

				L. E. Schmidt Nutrition Update: Practical Mineral Recommendations: Translation to Clinical Practice The Diabetes Educator, January 1, 1995; 21(1): 21 - 24. [PDF]